EU CE Marking under MDR and IVDR as a Global Registration Strategy
How CE technical documentation, clinical evaluation, GSPR, PMS, and notified-body review can support non-EU filings.
How to use it
Use MDR or IVDR technical documentation as the cross-country backbone for safety, performance, risk, clinical, labeling, PMS, and quality-system evidence.
Target markets where CE evidence is accepted as an overseas conformity assessment, reference approval, or high-quality technical-file template.
Positive impact
- Often the most reusable technical-file package for markets using GHTF, IMDRF, CSDT, or EU-aligned evidence structures.
- Can reduce duplicate work for clinical evaluation, ISO testing, risk management, GSPR/essential principles mapping, and PMS planning.
Limits and caveats
- CE marking does not replace local registration, importer or representative duties, local language labeling, or post-market reporting.
- Legacy MDD evidence may be weaker than MDR evidence in markets that now expect current clinical and PMS documentation.
Country impact matrix
Impact levels are conservative planning signals. Confirm the current accepted-reference list, product scope, and risk class before filing.